INT26294

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 1989
Last Reported 2009
Negated 0
Speculated 1
Reported most in Abstract
Documents 2
Total Number 3
Disease Relevance 1.73
Pain Relevance 0.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Gem) plasma membrane (Gem) GTPase activity (Gem)
Anatomy Link Frequency
B-cell 1
apoptotic cell 1
lung 1
Gem (Mus musculus)
Pain Link Frequency Relevance Heat
Immobilon 1 88.92 High High
Enkephalin 12 75.00 Quite High
opiate 1 62.64 Quite High
narcan 1 25.00 Low Low
Pain 1 25.00 Low Low
palliative 1 5.00 Very Low Very Low Very Low
Thoracotomy 1 5.00 Very Low Very Low Very Low
addiction 1 5.00 Very Low Very Low Very Low
Versed 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Toxicity 2 100.00 Very High Very High Very High
Apoptosis 60 98.68 Very High Very High Very High
Death 14 98.08 Very High Very High Very High
Non-small-cell Lung Cancer 19 95.72 Very High Very High Very High
Cancer 53 83.44 Quite High
Lung Cancer 10 71.76 Quite High
Fibrosarcoma 1 58.92 Quite High
Metastasis 1 55.36 Quite High
Disease 1 50.32 Quite High
Vomiting 2 25.00 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Effect of GEM and PB combination treatment on apoptotic cell death
Regulation (Effect) of GEM in apoptotic cell associated with apoptosis and death
1) Confidence 0.18 Published 2006 Journal J Carcinog Section Body Doc Link PMC1665446 Disease Relevance 0.86 Pain Relevance 0
Immunological studies indicated that MEA selectively enhanced the lymphoproliferative response to the T-cell mitogen, concanavalin A, but not to the B-cell mitogen, lipopolysaccharide.
Regulation (response) of T-cell mitogen in B-cell
2) Confidence 0.04 Published 1989 Journal Int. J. Immunopharmacol. Section Abstract Doc Link 2553621 Disease Relevance 0.50 Pain Relevance 0.60
The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection of PTS in peripherally advanced nonsmall cell lung cancer.
Spec (investigate) Regulation (response) of GEM in lung associated with toxicity and non-small-cell lung cancer
3) Confidence 0.03 Published 2009 Journal Anticancer Drugs Section Abstract Doc Link 19668080 Disease Relevance 0.38 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox